KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 108 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q3 2022. The put-call ratio across all filers is 0.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $247,314 | +23.4% | 14,238 | 0.0% | 0.05% | +19.5% |
| Q2 2023 | $200,471 | +30.9% | 14,238 | 0.0% | 0.04% | +28.1% |
| Q1 2023 | $153,201 | -28.2% | 14,238 | 0.0% | 0.03% | -28.9% |
| Q4 2022 | $213,285 | +16.5% | 14,238 | 0.0% | 0.04% | -2.2% |
| Q3 2022 | $183,000 | +23.6% | 14,238 | -6.6% | 0.05% | +31.4% |
| Q2 2022 | $148,000 | -13.5% | 15,238 | -11.6% | 0.04% | +2.9% |
| Q1 2022 | $171,000 | -15.8% | 17,238 | 0.0% | 0.03% | -10.5% |
| Q4 2021 | $203,000 | -19.8% | 17,238 | -22.5% | 0.04% | -26.9% |
| Q3 2021 | $253,000 | -31.6% | 22,238 | -16.2% | 0.05% | -31.6% |
| Q2 2021 | $370,000 | -23.9% | 26,538 | +1.1% | 0.08% | -27.6% |
| Q1 2021 | $486,000 | +4.7% | 26,238 | 0.0% | 0.10% | -8.7% |
| Q4 2020 | $464,000 | – | 26,238 | +20.9% | 0.12% | – |
| Q3 2020 | $0 | -100.0% | 21,700 | +10.2% | 0.00% | -100.0% |
| Q2 2020 | $502,000 | +64.6% | 19,700 | 0.0% | 0.15% | +35.5% |
| Q1 2020 | $305,000 | – | 19,700 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,025,000 | $12,064,000 | 2.56% |
| GREAT POINT PARTNERS LLC | 536,738 | $6,317,000 | 1.40% |
| Endurant Capital Management LP | 244,125 | $2,873,000 | 0.69% |
| HHLR ADVISORS, LTD. | 2,920,023 | $34,369,000 | 0.53% |
| Integral Health Asset Management, LLC | 140,000 | $1,648,000 | 0.46% |
| Spearhead Capital Advisors, LLC | 235,024 | $2,766,000 | 0.33% |
| Jackson Creek Investment Advisors LLC | 77,069 | $907,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 712,807 | $8,390,000 | 0.30% |
| Parkman Healthcare Partners LLC | 113,644 | $1,338,000 | 0.30% |
| Birchview Capital, LP | 30,000 | $353,000 | 0.23% |